{
    "Trade/Device Name(s)": [
        "Dexcom G7 Continuous Glucose Monitoring (CGM) System"
    ],
    "Submitter Information": "Dexcom, Inc.",
    "510(k) Number": "K231081",
    "Predicate Device Reference 510(k) Number(s)": [
        "K213919"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "QBJ"
    ],
    "Summary Letter Date": "May 15, 2023",
    "Summary Letter Received Date": "April 17, 2023",
    "Submission Date": "April 14, 2023",
    "Regulation Number(s)": [
        "21 CFR 862.1335"
    ],
    "Regulation Name(s)": [
        "Integrated Continuous Glucose Monitoring System"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Interstitial fluid"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Dexcom G7 CGM System (Glucose Sensing Subsystem, Mobile Application Subsystem, Receiver Subsystem)"
    ],
    "Method(s)/Technology(ies)": [
        "Amperometric measurement",
        "Glucose oxidase chemical reaction",
        "Wireless transmission"
    ],
    "Methodologies": [
        "Continuous glucose monitoring"
    ],
    "Submission Type(s)": [
        "System",
        "Sensor",
        "Mobile Application",
        "Receiver",
        "Accessory"
    ],
    "Document Summary": "FDA 510(k) summary for Dexcom G7 Continuous Glucose Monitoring System for real-time glucose measurement and management in diabetics aged 2 years and older.",
    "Indications for Use Summary": "Intended for real-time, continuous glucose monitoring to aid diabetes management in individuals 2 years and older, replacing fingerstick blood glucose testing for treatment decisions, including detection of hyper- and hypoglycemia and communication with automated insulin dosing systems.",
    "fda_folder": "Clinical Chemistry"
}